Pharvaris NV (PHVS) Q4 2025 Earnings Call Transcript

Why It Matters

The surge demonstrates Neffy's ability to expand the $2 billion U.S. epinephrine market and validates Pharvaris' commercial model, while the financing strengthens its runway for global scale.

Key Takeaways

• U.S. Neffy revenue $31.3M, 2.5x QoQ growth
• Market share among new prescribers 10.3%, leading growth
• 18,000 providers prescribed, 85% increase since August
• Global launches: Germany, UK, Japan; China 2026
• $250M term loan, $100M drawn, interest‑only till 2030

Pulse Analysis

Pharvaris’ latest earnings call highlighted a pivotal shift in the U.S. epinephrine landscape. Neffy’s $31.3 million net product revenue, driven by a 2.5‑fold quarter‑over‑quarter jump, reflects strong demand from both traditional retail channels and institutional sales that IQVIA data often miss. The company’s focused outreach to new prescribers has yielded a 10.3% market‑share advantage, while provider adoption surged 85% since August, underscoring the effectiveness of its refined messaging and virtual prescribing tools. This momentum is expanding the overall market, as 19% of users are lapsed patients and 7% are previously untreated, indicating that Neffy is not merely taking share but growing the total addressable pool.

Access initiatives are central to sustaining this growth. The Get Neffy On Us program eliminates prior‑authorization friction by offering virtual prescriptions at zero co‑pay for covered patients, a strategy that mitigates seasonal back‑to‑school slowdowns. Coupled with a direct‑to‑consumer campaign that lifted brand awareness from 20% to 56%, patient intent to request Neffy has risen sharply, translating into higher refill likelihood—87% report positive daily impact and 95% say they would refill, far outpacing needle‑injector benchmarks. These programs not only improve adherence but also broaden reach into schools and pediatric networks, reinforcing long‑term utilization.

Financially, Pharvaris entered a $250 million term loan facility, drawing $100 million with interest‑only payments through 2030, preserving cash while avoiding dilution. With $288 million in cash and short‑term investments, the firm projects cash‑flow breakeven without additional equity. Internationally, the rapid uptake of YERNEPI in Germany—three times the U.S. early trajectory—signals a scalable model for upcoming launches in the UK, Japan, Canada, and China. Together, robust commercial execution, patient‑centric access solutions, and a disciplined capital structure position Pharvaris to capture a larger share of the growing epinephrine market and unlock new revenue streams from upcoming label expansions such as chronic spontaneous urticaria.